X0508 4/A 2023-06-30 2023-07-05 0001965040 Fortrea Holdings Inc. FTRE 0001980205 Morais Mark A. 8 MOORE DRIVE DURHAM NC 27709 1 Chief Operating Officer 0 Restricted Stock Unit 2023-06-30 4 A 0 1260 0 A Common Stock 1260 1260 D Restricted Stock Unit 2023-06-30 4 A 0 527 0 A Common Stock 527 1787 D Restricted Stock Unit 2023-06-30 4 A 0 2420 0 A Common Stock 2420 4207 D Restricted Stock Unit 2023-06-30 4 A 0 6760 0 A Common Stock 6760 10967 D Restricted Stock Unit 2023-06-30 4 A 0 33013 0 A Common Stock 33013 43980 D Restricted Stock Unit 2023-06-30 4 A 0 812 0 A Common Stock 812 44792 D Restricted Stock Unit 2023-06-30 4 A 0 15368 0 A Common Stock 15368 60160 D Restricted Stock Unit 2023-06-30 4 A 0 1577 0 A Common Stock 1577 61737 D This Form 4 is amended to reflect the adjusted amount of Restricted Stock Units ("RSUs") issued to the Reporting Person in connection with the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Laboratory Corporation of America Holdings ("Labcorp") and Fortrea Holdings Inc. ("Fortrea"). Each RSU represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. In connection with the spin-off ("Spin-Off") of Fortrea by Labcorp, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. The RSUs will vest in full on February 2, 2024. This number reflects the aggregate number of Restricted Stock Units held by the reporting person. In connection with the Spin-Off, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The RSUs will vest in two annual installments on February 11 of each of 2024 and 2025. In connection with the Spin-Off, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The RSUs vest in three equal annual installments beginning on February 7, 2024. In connection with the Spin-Off, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The RSUs vest in three equal annual installments beginning on June 1, 2024. In connection with the Spin-Off, RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The RSUs will vest in two annual installments on December 15 of each of 2023 and 2024. In connection with the Spin-Off, performance awards granted by Labcorp in 2021 for the three-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Fortrea pursuant to the terms of the EMA. The 2021 PSA was converted into a number of time-vesting Fortrea RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting to occur on the 30th day following Labcorp's filing of an annual report with the SEC on Form 10-K that includes or incorporates by reference audited financial statements with respect to the 3-year period ending December 31, 2023. In connection with the Spin-Off, performance awards granted by Labcorp in 2022 for the three-year performance period through December 31, 2024 (the "2022 PSA") were converted into time-vesting RSUs of Fortrea and performance share awards of Fortrea pursuant to the terms of the EMA. The 2022 PSA was converted into a time-vesting Fortrea RSU equal to 50% of the target number of shares subject to the 2022 PSA, after application of the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting to occur on the 30th day following Labcorp's filing of an annual report with the SEC on Form 10-K that includes or incorporates by reference audited financial statements with respect to the 3-year period ending December 31, 2024, with the remainder of the 2022 PSA being converted into a performance share award of Fortrea that is not being reported on this Form. /s/ James Stillman Hanson, Attorney-in-Fact for Mark A. Morais 2023-07-19